MBL announces exclusive license agreement for Anti-Integrin αvβ6 Antibody with Immune-related Adverse Events colitis

Tokyo, Japan - May 13, 2024 - Medical ＆ Biological Laboratories Co., Ltd. (CEO: Hiroki Ito), a JSR Life Sciences Company, is pleased to announce that it has entered into an exclusive license agreement with Kyoto University and Kindai University regarding the detection of Anti-Integrin αvβ6 autoantibodies as an indicator of immune-related Adverse Events-related colitis (irAE colitis).

In April 2022, MBL concluded an exclusive license agreement with Kyoto University for the detection of Anti-Integrin αvβ6 autoantibodies, which are used as indicators of ulcerative colitis and primary sclerosing cholangitis. Because immunotherapy is clinically widespread in the field of oncology, MBL decided to also pursue an exclusive license related to the detection of Anti-Integrin avb6 autoantibodies as an indicator of irAE colitis.

The exclusive rights granted at this time is based on PCT/JP : 2023/037734 which are filed by Kyoto University and Kindai University.

Research reagents for measuring anti-integrin αvβ6 autoantibodies are already available. Please check the URL below for details.

Detail Product Information: https://www.mblbio.com/bio/g/dtl/P/?pcd=5288

Order or Inquiry: https://www.mblbio.com/bio/g/inq/index.html?pcd=5288&flg=1

About Anti-integrin avb6 antibody:

The anti-integrin αvβ6 antibody is an autoantibody against integrin αvβ6. Integrin is a cell surface receptor that is responsible for cell adhesion by binding to the extracellular matrix. In mammals, there are 24 different types of integrin. Integrin αvβ6 expressed in the intestinal epithelium is associated with suppression of inflammation and prevention of infection by pathogens and parasites.

About irAE colitis:

irAE colitis is a common adverse event associated with the administration of immune checkpoint inhibitors, and similarities with inflammatory bowel disease have been noted. Immune checkpoint inhibitors are drugs that maintain the ability of the immune system to attack cancer cells. However, because it over-activates not only the immune system against cancer but also in general, it can lead to autoimmune diseases that attack the body itself.

Product information:

[Research use only]

Product name: Anti-Integrin αvβ6 ELISA Kit

Code No.: 5288

Price (tax not included): 90,000 JPY

Package: 96 wells

Store: 2-8℃

Shelf life: 24 months

*This assay kit is for research use only and not for use in diagnostic or therapeutic procedures.

Contact:

Medical & Biological Laboratories Co., Ltd.

Technical Support

Head Quarter: SUMITOMO FUDOSAN SHIBADAIMON NICHOME BLDG. 2-11-8 Shibadaimon, Minato-ku, Tokyo 105-0012 Japan

TEL: +81-3-6684-6860 E-mail: https://www.mblbio.com/e/inq/ivd.html

Medical & Biological Laboratories (MBL) was established in 1969 as the first antibody manufacturer in Japan, and researches, develops, manufactures, and sells reagents of in vitro diagnostics (IVD) and reagents for basic research. It has now expanded its business not only to the immunological field but also to the field of genetic diagnosis.

In the IVD business, we develop and sell IVD reagents for autoimmune diseases, cancer, infectious diseases, etc. Particularly in the field of autoantibody diagnosis, we are expanding our product lineup as a top manufacturer in Japan and contributing to medical care in this field where there are many intractable diseases. In the field of oncology, we are contributing to personalized medicine by developing companion diagnostics that predict the effects of drugs.